| P50 | author | Marianthi Markatou | Q79293916 |
| P2093 | author name string | Andrew H Talal | |
| | Gene D Morse | |
| | Yvonne Woolwine-Cunningham | |
| | Charles S Venuto | |
| | Robin DiFrancesco | |
| | Emily O Dumas | |
| | Paul K Wallace | |
| | Andrew J Ocque | |
| | Rosemary Furlage | |
| P2860 | cites work | Statistical methods for assessing agreement between two methods of clinical measurement | Q26778461 |
| | Efficient hepatic delivery of drugs: novel strategies and their significance | Q27007518 |
| | Measuring agreement in method comparison studies | Q28145208 |
| | PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel | Q33533523 |
| | Liver biopsy | Q33932981 |
| | Comparison of fine needle aspiration cytology and needle core biopsy in the diagnosis of radiologically detected abdominal lesions | Q34543640 |
| | Approaches to liver biopsy techniques--revisited | Q34575197 |
| | Telaprevir-based treatment effects on hepatitis C virus in liver and blood | Q35129251 |
| | Imperfect drug penetration leads to spatial monotherapy and rapid evolution of multidrug resistance | Q35699612 |
| | Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue | Q35754443 |
| | Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies | Q36445132 |
| | Liver-to-plasma vaniprevir (MK-7009) concentration ratios in HCV-infected patients | Q36468240 |
| | Gene expression analysis in serial liver fine needle aspirates | Q36487934 |
| | Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers | Q36806650 |
| | Development and validation of a UPLC-MS/MS method for the simultaneous determination of paritaprevir and ritonavir in rat liver | Q37046055 |
| | Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. | Q37121662 |
| | Role of the murine organic anion-transporting polypeptide 1b2 (Oatp1b2) in drug disposition and hepatotoxicity | Q37168820 |
| | Determination of intracellular unbound concentrations and subcellular localization of drugs in rat sandwich-cultured hepatocytes compared with liver tissue. | Q37251993 |
| | Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver | Q37504548 |
| | Fine needle aspiration in the diagnosis of liver neoplasms: a review | Q37685722 |
| | Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science | Q37790383 |
| | Functions of OATP1A and 1B transporters in vivo: insights from mouse models | Q37963157 |
| | Drug targeting to the diseased liver | Q37988733 |
| | Species differences in drug transporters and implications for translating preclinical findings to humans | Q38068912 |
| | Role of hepatic efflux transporters in regulating systemic and hepatocyte exposure to xenobiotics. | Q38155591 |
| | Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir | Q40697687 |
| | Intrahepatic antiviral quantification in a patient undergoing orthotopic cadaveric liver transplantation | Q42680456 |
| | Comparison of EUS-guided tissue acquisition using two different 19-gauge core biopsy needles: a multicenter, prospective, randomized, and blinded study | Q43211395 |
| | Is it important to correct apparent drug tissue concentrations for blood contamination in the dog? | Q44898814 |
| | How we assess adequacy of fine-needle aspiration materials intended for flow cytometric analysis | Q46663994 |
| | Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements. | Q50773884 |
| | Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans | Q73234143 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ritonavir | Q422618 |
| | paritaprevir | Q16824572 |
| P577 | publication date | 2017-03-06 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling Techniques | |
| P478 | volume | 61 | |